{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:51:08Z","timestamp":1762458668428},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1007\/s11060-008-9721-3","type":"journal-article","created":{"date-parts":[[2008,10,31]],"date-time":"2008-10-31T01:46:08Z","timestamp":1225417568000},"page":"265-270","source":"Crossref","is-referenced-by-count":17,"title":["A role for the p53 pathway in the pathology of meningiomas with NF2 loss"],"prefix":"10.1007","volume":"91","author":[{"given":"ZeNan","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Lin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Ahronowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat O.","family":"Stemmer-Rachamimov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"MacCollin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio P.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,11,1]]},"reference":[{"key":"9721_CR1","volume-title":"Greenfield\u2019s neuropathology","author":"PL Lantos","year":"2002","unstructured":"Lantos PL, VandenBerg SR, Kleihues P (2002) Tumours of the nervous system. In: Graham DL, Lantos PL (eds) Greenfield\u2019s neuropathology. Arnold, London"},{"key":"9721_CR2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/gcc.2870100207","volume":"10","author":"MH Ruttledge","year":"1994","unstructured":"Ruttledge MH, Xie YG, Han FY et al (1994) Deletions on chromosome 22 in sporadic meningioma. Genes Chromosomes Cancer 10:122\u2013130. doi: 10.1002\/gcc.2870100207","journal-title":"Genes Chromosomes Cancer"},{"key":"9721_CR3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0294-180","volume":"6","author":"MH Ruttledge","year":"1994","unstructured":"Ruttledge MH, Sarrazin J, Rangaratnam S et al (1994) Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 6:180\u2013184. doi: 10.1038\/ng0294-180","journal-title":"Nat Genet"},{"key":"9721_CR4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/00005072-199503000-00009","volume":"54","author":"RH Lekanne Deprez","year":"1995","unstructured":"Lekanne Deprez RH, Riegman PH, van Drunen E et al (1995) Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas. J Neuropathol Exp Neurol 54:224\u2013235. doi: 10.1097\/00005072-199503000-00009","journal-title":"J Neuropathol Exp Neurol"},{"key":"9721_CR5","first-page":"5995","volume":"59","author":"K Ueki","year":"1999","unstructured":"Ueki K, Wen-Bin C, Narita Y et al (1999) Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res 59:5995\u20135998","journal-title":"Cancer Res"},{"key":"9721_CR6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cancergencyto.2005.04.003","volume":"162","author":"F Nunes","year":"2005","unstructured":"Nunes F, Shen Y, Niida Y et al (2005) Inactivation patterns of NF2 and DAL-1\/4.1B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet 162:135\u2013139. doi: 10.1016\/j.cancergencyto.2005.04.003","journal-title":"Cancer Genet Cytogenet"},{"key":"9721_CR7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3171\/jns.2004.101.2.0210","volume":"101","author":"O Al-Mefty","year":"2004","unstructured":"Al-Mefty O, Kadri PA, Pravdenkova S et al (2004) Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg 101:210\u2013218","journal-title":"J Neurosurg"},{"key":"9721_CR8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/jnen\/63.4.275","volume":"63","author":"K Lamszus","year":"2004","unstructured":"Lamszus K (2004) Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 63:275\u2013286","journal-title":"J Neuropathol Exp Neurol"},{"key":"9721_CR9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.2649981","volume":"244","author":"SJ Baker","year":"1989","unstructured":"Baker SJ, Fearon ER, Nigro JM et al (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217\u2013221. doi: 10.1126\/science.2649981","journal-title":"Science"},{"key":"9721_CR10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","volume":"88","author":"AJ Levine","year":"1997","unstructured":"Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323\u2013331. doi: 10.1016\/S0092-8674(00)81871-1","journal-title":"Cell"},{"key":"9721_CR11","first-page":"3551","volume":"22","author":"M Hollstein","year":"1994","unstructured":"Hollstein M, Rice K, Greenblatt MS et al (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3551\u20133555","journal-title":"Nucleic Acids Res"},{"key":"9721_CR12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1015-9584(09)60249-9","volume":"28","author":"A Das","year":"2005","unstructured":"Das A, Tan WL, Smith DR (2005) p53 point mutation is rare in meningiomas from Singaporean patients. Asian J Surg 28:7\u201310","journal-title":"Asian J Surg"},{"key":"9721_CR13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1365-2990.1995.tb01040.x","volume":"21","author":"DW Ellison","year":"1995","unstructured":"Ellison DW, Lunec J, Gallagher PJ et al (1995) Accumulation of wild-type p53 in meningiomas. Neuropathol Appl Neurobiol 21:136\u2013142. doi: 10.1111\/j.1365-2990.1995.tb01040.x","journal-title":"Neuropathol Appl Neurobiol"},{"key":"9721_CR14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/mc.2940080203","volume":"8","author":"H Ohgaki","year":"1993","unstructured":"Ohgaki H, Eibl RH, Schwab M et al (1993) Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 8:74\u201380. doi: 10.1002\/mc.2940080203","journal-title":"Mol Carcinog"},{"key":"9721_CR15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/A:1005779406636","volume":"32","author":"MJ Pykett","year":"1997","unstructured":"Pykett MJ, Landers J, George DL (1997) Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas. J Neurooncol 32:39\u201344. doi: 10.1023\/A:1005779406636","journal-title":"J Neurooncol"},{"key":"9721_CR16","unstructured":"Hei Y, Zhang XW, Wang Y, et al (2006). The features of pathology and immunohistochemistry in orbital meningiomas. Zhonghua Yan Ke Za Zhi 42:998\u20131001"},{"key":"9721_CR17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1005946001915","volume":"38","author":"M Ohkoudo","year":"1998","unstructured":"Ohkoudo M, Sawa H, Hara M et al (1998) Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas. J Neurooncol 38:41\u201349. doi: 10.1023\/A:1005946001915","journal-title":"J Neurooncol"},{"key":"9721_CR18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/modpathol.3800111","volume":"17","author":"VJ Amatya","year":"2004","unstructured":"Amatya VJ, Takeshima Y, Inai K (2004) Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation. Mod Pathol 17:705\u2013710. doi: 10.1038\/modpathol.3800111","journal-title":"Mod Pathol"},{"key":"9721_CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11060-006-9301-3","volume":"83","author":"HH Al-Khalaf","year":"2007","unstructured":"Al-Khalaf HH, Lach B, Allam A et al (2007) The p53\/p21 DNA damage-signaling pathway is defective in most meningioma cells. J Neurooncol 83:9\u201315. doi: 10.1007\/s11060-006-9301-3","journal-title":"J Neurooncol"},{"key":"9721_CR20","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1074\/jbc.M305526200","volume":"279","author":"H Kim","year":"2004","unstructured":"Kim H, Kwak NJ, Lee JY et al (2004) Merlin neutralizes the inhibitory effect of Mdm2 on p53. J Biol Chem 279:7812\u20137818. doi: 10.1074\/jbc.M305526200","journal-title":"J Biol Chem"},{"key":"9721_CR21","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0092-8674(92)90644-R","volume":"69","author":"J Momand","year":"1992","unstructured":"Momand J, Zambetti GP, Olson DC et al (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237\u20131245. doi: 10.1016\/0092-8674(92)90644-R","journal-title":"Cell"},{"key":"9721_CR22","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1101\/gad.11.15.1974","volume":"11","author":"CJ Thut","year":"1997","unstructured":"Thut CJ, Goodrich JA, Tjian R (1997) Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev 11:1974\u20131986. doi: 10.1101\/gad.11.15.1974","journal-title":"Genes Dev"},{"key":"9721_CR23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","volume":"387","author":"Y Haupt","year":"1997","unstructured":"Haupt Y, Maya R, Kazaz A et al (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296\u2013299. doi: 10.1038\/387296a0","journal-title":"Nature"},{"key":"9721_CR24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-5793(97)01480-4","volume":"420","author":"R Honda","year":"1997","unstructured":"Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25\u201327. doi: 10.1016\/S0014-5793(97)01480-4","journal-title":"FEBS Lett"},{"key":"9721_CR25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/387299a0","volume":"387","author":"MH Kubbutat","year":"1997","unstructured":"Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299\u2013303. doi: 10.1038\/387299a0","journal-title":"Nature"},{"key":"9721_CR26","first-page":"829","volume":"8","author":"JM Jones","year":"1997","unstructured":"Jones JM, Attardi L, Godley LA et al (1997) Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ 8:829\u2013838","journal-title":"Cell Growth Differ"},{"key":"9721_CR27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature05194","volume":"444","author":"NA Laurie","year":"2006","unstructured":"Laurie NA, Donovan SL, Shih CS et al (2006) Inactivation of the p53 pathway in retinoblastoma. Nature 444:61\u201366. doi: 10.1038\/nature05194","journal-title":"Nature"},{"key":"9721_CR28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cell.2004.11.022","volume":"119","author":"GL Bond","year":"2004","unstructured":"Bond GL, Hu W, Bond EE et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591\u2013602. doi: 10.1016\/j.cell.2004.11.022","journal-title":"Cell"},{"key":"9721_CR29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/1541-7786.MCR-06-0238","volume":"5","author":"TK Ku","year":"2007","unstructured":"Ku TK, Nguyen DC, Karaman M et al (2007) Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer. Mol Cancer Res 5:351\u2013362. doi: 10.1158\/1541-7786.MCR-06-0238","journal-title":"Mol Cancer Res"},{"key":"9721_CR30","doi-asserted-by":"crossref","first-page":"6728","DOI":"10.1128\/MCB.24.15.6728-6741.2004","volume":"24","author":"S Erster","year":"2004","unstructured":"Erster S, Mihara M, Kim RH et al (2004) In\u00a0vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 24:6728\u20136741. doi: 10.1128\/MCB.24.15.6728-6741.2004","journal-title":"Mol Cell Biol"},{"key":"9721_CR31","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.emboj.7601560","volume":"26","author":"ND Marchenko","year":"2007","unstructured":"Marchenko ND, Wolff S, Erster S et al (2007) Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J 26:923\u2013934. doi: 10.1038\/sj.emboj.7601560","journal-title":"EMBO J"},{"key":"9721_CR32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0014-5793(00)02368-1","volume":"488","author":"C Sansome","year":"2001","unstructured":"Sansome C, Zaika A, Marchenko ND et al (2001) Hypoxia death stimulus induces translocation of p53 protein to mitochondria. Detection by immunofluorescence on whole cells. FEBS Lett 488:110\u2013115. doi: 10.1016\/S0014-5793(00)02368-1","journal-title":"FEBS Lett"},{"key":"9721_CR33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ng1093","volume":"33","author":"P Dumont","year":"2003","unstructured":"Dumont P, Leu JI, Della Pietra AC 3rd et al (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357\u2013365. doi: 10.1038\/ng1093","journal-title":"Nat Genet"},{"key":"9721_CR34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/75586","volume":"25","author":"MC Marin","year":"2000","unstructured":"Marin MC, Jost CA, Brooks LA et al (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25:47\u201354. doi: 10.1038\/75586","journal-title":"Nat Genet"},{"key":"9721_CR35","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1158\/1078-0432.CCR-05-0173","volume":"11","author":"J Tommiska","year":"2005","unstructured":"Tommiska J, Eerola H, Heinonen M et al (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098\u20135103. doi: 10.1158\/1078-0432.CCR-05-0173","journal-title":"Clin Cancer Res"},{"key":"9721_CR36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ijc.10840","volume":"103","author":"B Heinrich","year":"2003","unstructured":"Heinrich B, Hartmann C, Stemmer-Rachamimov AO et al (2003) Multiple meningiomas: investigating the molecular basis of sporadic and familial forms. Int J Cancer 103:483\u2013488. doi: 10.1002\/ijc.10840","journal-title":"Int J Cancer"},{"key":"9721_CR37","first-page":"1037","volume":"9","author":"R Fan","year":"2000","unstructured":"Fan R, Wu MT, Miller D et al (2000) The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 9:1037\u20131042","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"9721_CR38","volume-title":"Pathology and genetics of tumours of the nervous system","year":"2000","unstructured":"Kleihues P, Cavenee WK (eds) (2000) Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer, Lyon"},{"key":"9721_CR39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJM200101113440207","volume":"344","author":"LM DeAngelis","year":"2001","unstructured":"DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114\u2013123. doi: 10.1056\/NEJM200101113440207","journal-title":"N Engl J Med"},{"key":"9721_CR40","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1158\/1055-9965.EPI-05-0234","volume":"14","author":"B Malmer","year":"2005","unstructured":"Malmer B, Feychting M, Lonn S et al (2005) p53 Genotypes and risk of glioma and meningioma. Cancer Epidemiol Biomarkers Prev 14:2220\u20132223. doi: 10.1158\/1055-9965.EPI-05-0234","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"9721_CR41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2407-5-105","volume":"5","author":"I Sturm","year":"2005","unstructured":"Sturm I, Bosanquet AG, Hummel M et al (2005) In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer 5:105. doi: 10.1186\/1471-2407-5-105","journal-title":"BMC Cancer"},{"key":"9721_CR42","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-006-9275-1","volume":"82","author":"BS Malmer","year":"2007","unstructured":"Malmer BS, Feychting M, Lonn S et al (2007) Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol 82:229\u2013237. doi: 10.1007\/s11060-006-9275-1","journal-title":"J Neurooncol"},{"key":"9721_CR43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.33549\/physiolres.930134","volume":"51","author":"E Biros","year":"2002","unstructured":"Biros E, Kalina I, Kohut A et al (2002) Allelic and haplotype frequencies of the p53 polymorphisms in brain tumor patients. Physiol Res 51:59\u201364","journal-title":"Physiol Res"},{"key":"9721_CR44","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3171\/jns.1984.60.5.0985","volume":"60","author":"DW Cahill","year":"1984","unstructured":"Cahill DW, Bashirelahi N, Solomon LW et al (1984) Estrogen and progesterone receptors in meningiomas. J Neurosurg 60:985\u2013993","journal-title":"J Neurosurg"},{"key":"9721_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-006-9146-9","volume":"80","author":"K Korhonen","year":"2006","unstructured":"Korhonen K, Salminen T, Raitanen J et al (2006) Female predominance in meningiomas cannot be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol 80:1\u20137. doi: 10.1007\/s11060-006-9146-9","journal-title":"J Neurooncol"},{"key":"9721_CR46","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1101\/gad.226302","volume":"16","author":"M Kalamarides","year":"2002","unstructured":"Kalamarides M, Niwa-Kawakita M, Leblois H et al (2002) Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 16:1060\u20131065. doi: 10.1101\/gad.226302","journal-title":"Genes Dev"},{"key":"9721_CR47","first-page":"219","volume":"24","author":"O Ozen","year":"2005","unstructured":"Ozen O, Demirhan B, Altinors N (2005) Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Clin Neuropathol 24:219\u2013224","journal-title":"Clin Neuropathol"},{"key":"9721_CR48","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1074\/jbc.M108302200","volume":"277","author":"LD Mayo","year":"2002","unstructured":"Mayo LD, Dixon JE, Durden DL et al (2002) PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277:5484\u20135489. doi: 10.1074\/jbc.M108302200","journal-title":"J Biol Chem"},{"key":"9721_CR49","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0092-8674(00)81400-2","volume":"92","author":"J Pomerantz","year":"1998","unstructured":"Pomerantz J, Schreiber-Agus N, Liegeois NJ et al (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2\u2019s inhibition of p53. Cell 92:713\u2013723. doi: 10.1016\/S0092-8674(00)81400-2","journal-title":"Cell"},{"key":"9721_CR50","doi-asserted-by":"crossref","first-page":"8371","DOI":"10.1074\/jbc.274.13.8371","volume":"274","author":"RV Sionov","year":"1999","unstructured":"Sionov RV, Moallem E, Berger M et al (1999) c-Abl neutralizes the inhibitory effect of Mdm2 on p53. J Biol Chem 274:8371\u20138374. doi: 10.1074\/jbc.274.13.8371","journal-title":"J Biol Chem"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-008-9721-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-008-9721-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-008-9721-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T06:31:46Z","timestamp":1709361106000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-008-9721-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,1]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["9721"],"URL":"https:\/\/doi.org\/10.1007\/s11060-008-9721-3","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,1]]}}}